-related side effects. its manufacturer, eli lilly, plans to submit a new drug application to the fda in the second half of 2018..
executive director of saen michael budkie made these reports public in a letter addressed to chancellor carol christ on wednesday..: "fremanezumab for the preventive treatment of chronic migraine.".
..© 2018 cable news network..